Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

Protein Kinase Inhibitor Therapy in Advanced Thyroid Cancer: Ethical Challenges and Potential Solutions
Bible, Keith C. , Rosenthal, M. Sara, Ain, Kenneth B.

Mayo Clinic

International Journal of Endocrine Oncology | December 12, 2014 | Volume: 1 | Issue: 2 | Pages: 145-151

10.2217/ije.14.24 Get It

Control of Diabetic Diarrhea with Antibiotic Therapy
Berge, Kenneth G., Sprague, Randall G., Green, Paul A

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 17 | Issue: 6 | Pages: 385-387

10.2337/diab.17.6.385 | PMID 5652471 Get It

The ability of oral antibiotic treatment to control diabetic diarrhea was documented by a double-blind study involving a patient with this condition. When the patient was given Mysteclin-F, the diarrhea subsided promptly, only to recur when a placebo was substituted,. The erratic behavior of diabetic diarrhea is indicated, however, by the fact that a remission eventually occurred, and no further treatment was required. Although not all patients with diabetic diarrhea respond to antibiotic treatment, its trial merits consideration forthose patients who are refractory to the simpler forms of treatment.
The Intestinal Tract in Diabetic Diarrhea: A Pathologic Study
Berge, Kenneth G., Sprague, Randall G., Bennett, Warren A.

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 5 | Issue: 4 | Pages: 289-294

10.2337/diab.5.4.289 | PMID 13356718 Get It

Steatorrhea Complicating Diabetes Mellitus with Neuropathy: Report of Cases without Apparent External Pancreatic Insufficiency
Berge, Kenneth G., Wollaeger, Eric E., Scholz, D, Rooke, E. Douglas , Sprague, Randall G.

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 5 | Issue: 1 | Pages: 25-31

10.2337/diab.5.1.25 | PMID 13294004 Get It

Disturbances of gastrointestinal function have frequently been observed in association with diabetes mellitus. The disorders which have been reported include gastric atony and dilatation, postprandial abdominal cramping, severe constipation, and intractable diarrhea characterized by watery stools, nocturnal exacerbations and fecal incontinence. These disturbances have been attributed by many investigators to alterations in gastrointestinal motility secondary to visceral diabetic neuropathy. The purpose of the present report is to call attention to a group of patients with diabetes mellitus and neuropathy who exhibited diarrhea and steatorrhea which apparently could not be attributed to external pancreatic insufficiency.
Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections
Noel, Pawan, Patel, Krutika , Durgampudi, Chandra, Trivedi, Ram N., Oliveira, Cristiane de , Pannala, Rahul , Lee, Kenneth , Chennat, Jennifer, Slivka, Adam, Khalid, Asif , DeLany, James P. , Cline, Rachel, Acharya, Chathur , Jaligama, Deepthi, Murad, Faris, Yadav, Dhiraj , Navina, Sarah, Singh, Vijay , de Oliveira, Cristiane, Singh, Vijay P, Crowell, Michael D. , Brand, Randall E. , Papachristou, Georgios I. , Whitcomb, David C. , Singh, Vijay P

Mayo Clinic

Gut | December 10, 2014 | Volume: 65 | Issue: 1 | Pages: 100-111

10.1136/gutjnl-2014-308043 | PMID 25500204 Get It

Background and aims Peripancreatic fat necrosis occurs frequently in necrotising pancreatitis. Distinguishing markers from mediators of severe acute pancreatitis (SAP) is important since targeting mediators may improve outcomes. We evaluated potential agents in human pancreatic necrotic collections (NCs), pseudocysts (PCs) and pancreatic cystic neoplasms and used pancreatic acini, peripheral blood mononuclear cells (PBMC) and an acute pancreatitis (AP) model to determine SAP mediators. Methods We measured acinar and PBMC injury induced by agents increased in NCs and PCs. Outcomes of caerulein pancreatitis were studied in lean rats coadministered interleukin (IL)-1β and keratinocyte chemoattractant/growth-regulated oncogene, triolein alone or with the lipase inhibitor orlistat. Results NCs had higher fatty acids, IL-8 and IL-1β versus other fluids. Lipolysis of unsaturated triglyceride and resulting unsaturated fatty acids (UFA) oleic and linoleic acids induced necro-apoptosis at less than half the concentration in NCs but other agents did not do so at more than two times these concentrations. Cytokine coadministration resulted in higher pancreatic and lung inflammation than caerulein alone, but only triolein coadministration caused peripancreatic fat stranding, higher cytokines, UFAs, multisystem organ failure (MSOF) and mortality in 97% animals, which were prevented by orlistat. Conclusions UFAs, IL-1β and IL-8 are elevated in NCs. However, UFAs generated via peripancreatic fat lipolysis causes worse inflammation and MSOF, converting mild AP to SAP.
Stereotactic Body Radiotherapy for Metastatic and Recurrent Ewing Sarcoma and Osteosarcoma
Brown, Lindsay C. , Lester, Rachael, Haddock, Michael G. , Olivier, Kenneth R. , Arndt, Carola A.S., Rose, Peter S. , Lester, Rachael A, Grams, Michael P. , Laack, Nadia N.

Mayo Clinic

Sarcoma | December 9, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-9

10.1155/2014/418270 | PMID 25548538 Get It

Background. Radiotherapy has been utilized for metastatic and recurrent osteosarcoma and Ewing sarcoma (ES), in order to provide palliation and possibly prolong overall or progression-free survival. Stereotactic body radiotherapy (SBRT) is convenient for patients and offers the possibility of increased efficacy. We report our early institutional experience using SBRT for recurrent and metastatic osteosarcoma and Ewing sarcoma.Methods. We reviewed all cases of osteosarcoma or ES treated with SBRT between 2008 and 2012.Results. We identified 14 patients with a total of 27 lesions from osteosarcoma(n=19)or ES(n=8). The median total curative/definitive SBRT dose delivered was 40 Gy in 5 fractions (range, 30–60 Gy in 3–10 fractions). The median total palliative SBRT dose delivered was 40 Gy in 5 fractions (range, 16–50 Gy in 1–10 fractions). Two grade 2 and 1 grade 3 late toxicities occurred, consisting of myonecrosis, avascular necrosis with pathologic fracture, and sacral plexopathy. Toxicity was seen in the settings of concurrent chemotherapy and reirradiation.Conclusions. This descriptive report suggests that SBRT may be a feasible local treatment option for patients with osteosarcoma and ES. However, significant toxicity can result, and thus systematic study is warranted to clarify efficacy and characterize long-term toxicity.
Nitrate and nitrite ingestion and risk of ovarian cancer among postmenopausal women in Iowa
Inoue‐Choi, Maki , Jones, Rena R. , Anderson, Kristin E. , Cantor, Kenneth P., Krasner, Stuart W. , Robien, Kim , Weyer, Peter J., Cerhan, James R. , Ward, Mary H.

Mayo Clinic

International Journal of Cancer | November 27, 2014 | Volume: 137 | Issue: 1 | Pages: 173-182

10.1002/ijc.29365 | PMID 25430487 Get It

Nitrate and nitrite are precursors in the endogenous formation of N‐nitroso compounds (NOC), potential human carcinogens. We evaluated the association of nitrate and nitrite ingestion with postmenopausal ovarian cancer risk in the Iowa Women's Health Study. Among 28,555 postmenopausal women, we identified 315 incident epithelial ovarian cancers from 1986 to 2010. Dietary nitrate and nitrite intakes were assessed at baseline using food frequency questionnaire data. Drinking water source at home was obtained in a 1989 follow‐up survey. Nitrate‐nitrogen (NO3‐N) and total trihalomethane (TTHM) levels for Iowa public water utilities were linked to residences and average levels were computed based on each woman's duration at the residence. We computed multivariable‐adjusted hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazards regression. We tested interactions of nitrate with TTHMs and dietary factors known to influence NOC formation. Ovarian cancer risk was 2.03 times higher (CI = 1.22–3.38, ptrend = 0.003) in the highest quartile (≥2.98 mg/L) compared with the lowest quartile (≤0.47 mg/L; reference) of NO3‐N in public water, regardless of TTHM levels. Risk among private well users was also elevated (HR = 1.53, CI = 0.93–2.54) compared with the same reference group. Associations were stronger when vitamin C intake was <median (pinteraction = 0.01 and 0.33 for private well and public supplies, respectively). Dietary nitrate was inversely associated with ovarian cancer risk (ptrend = 0.02); whereas, dietary nitrite from processed meats was positively associated with the risk (ptrend = 0.04). Our findings indicate that high nitrate levels in public drinking water and private well use may increase ovarian cancer risk among postmenopausal women.
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
Rodeberg, David A. , Wharam, Moody D., Lyden, Elizabeth , Stoner, Julie A., Brown, Kenneth L., Paidas, Charles N. , Donaldson, Sarah S. , Hawkins, Douglas S. , Spunt, Sheri L. , Arndt, Carola A.S., Wolden, Suzanne L. , Hawkins, Douglas S , Spunt, Sheri L , Donaldson, Sarah S

Mayo Clinic

International Journal of Cancer | November 21, 2014 | Volume: 137 | Issue: 1 | Pages: 204-211

10.1002/ijc.29351 | PMID 25418440 Get It

The majority of intermediate‐risk rhabdomyosarcoma (RMS) patients have gross residual disease (Group III) after their first operative procedure. It is currently not known if local control rates can be maintained when, following induction chemotherapy, the radiation therapy (RT) dose is decreased after a delayed primary excision (DPE). To answer this question we evaluated patients enrolled on COG D9803 (1999–2005) who had Group III tumors of the bladder dome, extremity or trunk (thorax, abdomen and pelvis) were candidates for DPE at Week 12 if the primary tumor appeared resectable. RT dose was then adjusted by the completeness of DPE: no evidence of disease 36 Gy, microscopic residual 41.4 Gy and gross residual disease (GRD) 50.4 Gy. A total of 161 Group III patients were evaluated (24 bladder dome, 63 extremity and 74 trunk). Seventy‐three patients (45%) underwent DPE which achieved removal of all gross disease in 61 (84%) who were then eligible for reduced RT dose (43/73 received 36 Gy, 19/73 received 41.4 Gy). The local 5‐year failure rate (0% for bladder dome, 7% for extremity and 20% for trunk) was similar to IRS‐IV, which did not encourage DPE and did not allow for DPE adapted RT dose reduction. In conclusion, DPE was performed in 45% of Group III RMS patients with tumors at select anatomic sites (bladder dome, extremity and trunk) and 84% of those who had DPE were eligible for RT dose reduction. Local control outcomes were similar to historic results with RT alone.
The Rare Cancer Network: Ongoing Studies and Future Strategy
Özşahin, Mahmut , Mirimanoff, René-Olivier, Thariat, Juliette , Sun, Xu , Atalar, Banu , Lassen–Ramshad, Yasmin , Uğurluer, Gamze , Hallemeier, Christopher L. , Houtte, Paul Van , Krengli, Marco , Zhang, Lan Jun, Funk, Ryan K., Rooney, Jessica, Miller, Robert C. , Hallemeier, Christopher, Chang, Kenneth , Funk, Ryan, Mirimanoff, R.O., Krishnan, Sunil , Hallemeier, Christopher Leigh , Chang, Kenneth Tou En , Thariat, Juliette

Mayo Clinic

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 91-94

10.4081/rt.2014.5465 | PMID 25276326 Get It

The Rare Cancer Network (RCN) was formed in the early 1990's to create a global network that could pool knowledge and resources in the studies of rare malignancies whose infrequency prevented both their study with prospective clinical trials. To date, the RCN has initiated 74 studies resulting in 46 peer reviewed publications. The First International Symposium of the Rare Cancer Network took place in Nice in March of 2014. Status updates and proposals for new studies were heard for fifteen topics. Ongoing studies continue for cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas. New proposals were presented at the symposium for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, tumors of the ampulla of Vater, salivary gland tumors, anorectal melanoma, midline nuclear protein in testes carcinoma, pulmonary lymphoepithelioma-like carcinoma, adenoid cystic carcinoma of the trachea, osteosarcomas of the mandible, and extra-cranial hemangiopericytoma. This manuscript presents the abstracts of those proposals and updates on ongoing studies, as well a brief summary of the vision and future of the RCN.